What is the 13F Pro Quality Score for RMD?

13F Pro ranks RESMED INC (RMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RMD's current score at https://13fpro.ai/research/RMD (free sign-up required for the full ranking).

Where does 13F Pro source RMD data?

All RESMED INC fundamentals and ownership data come directly from SEC EDGAR. RESMED INC files with the SEC under CIK 943819. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RMD in?

RESMED INC (RMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives RMD's revenue?

Per RESMED INC's latest 10-Q filed with the SEC on 2026-05-01, the biggest revenue drivers are: Sleep and Breathing Health ($3,685.9M, +11% YoY); Residential Care Software ($503.9M, +6% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/RMD.

What are RMD's largest expenses?

RESMED INC's latest 10-Q reports these as the largest expense items: Cost of sales ($1,575.8M, +2% YoY); Selling, general, and administrative ($823.2M, +13% YoY); Research and development ($272.6M, +11% YoY). Sourced directly from SEC EDGAR filing text for Q3 FY2026 (nine months ended March 31, 2026).

How often is RMD research updated on 13F Pro?

RMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RESMED INC(RMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 943819 RMD stock profile & AI dashboard →

13F Pro Quality Score

79.8/100

Rank #50 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

65.0/100

Profitability

90.4/100

Balance Sheet

96.0/100

Earnings Quality

72.8/100

Free Cash Flow

87.6/100

Institutional Flow

69.0/100

Revenue Scale

79.4/100

Dilution Risk

43.1/100

RMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for RESMED INC (RMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RMD at 79.8/100 on a 32-signal composite quality model, placing it at rank #50 of 2,879 stocks — the top 5% of the AI-ranked universe. RMD scores in the top quartile across balance sheet strength (96.0), profitability (90.4), free cash flow (87.6). Shareholder dilution risk is elevated at 43.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), RESMED INC reports quarterly revenue of $1.4B, net income of $398.7M, an operating margin of 34.9%. Top institutional holders of RMD by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. RMD trades on the NYSE exchange and files with the SEC under CIK 943819. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RESMED INC directly from SEC EDGAR. RESMED INC's 13F Pro composite quality score has ranged between 8 and 84 since 2021, currently 79.8 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about RESMED INC

Quirks, history, and lore behind RMD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · mid-to-large cap · listed on the NYSE · headquartered in San Diego, California with major operations in Australia.
2
The Numbers
Annual revenue in the range of $4 billion, serving patients in over 140 countries — a surprisingly global footprint for a company most people have never heard of.
3
The History
Founded in Australia in the 1980s by a physician-entrepreneur who believed a common sleep disorder was being dangerously undertreated, it later dual-listed and planted its commercial roots in San Diego.
4
The Secret
It doesn't just sell hardware — a huge chunk of its business is cloud-connected software that remotely monitors patients every night while they sleep, generating sticky subscription-style revenue.
5
The Lore
When a rival's products were recalled over safety concerns in the early 2020s, this company's stock surged dramatically as millions of patients needed an alternative — a textbook case of one competitor's nightmare being another's windfall.
6
The Giveaway
It is the world's leading maker of CPAP machines and masks for sleep apnea — if you or someone you love wears a breathing mask to bed, there's a good chance this company made it.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving RMD's Business? Latest 10-Q Breakdown

AI-extracted from RESMED INC's 10-Q filed 2026-05-01 — Q3 FY2026 (nine months ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

ResMed posted $4.2B in revenue (+10% YoY) with 21.1% effective tax rate and $1.1B net income, driven by 11% Sleep and Breathing Health growth and 6% Residential Care Software expansion.

Biggest Revenue Drivers

Total revenue: $4,189.8M+10% YoY

Sleep and Breathing Health$3,685.9M+11% YoY

Increased demand and unit sales of devices and masks, partially benefiting from favorable foreign currency movements (+$71.2M).

Residential Care Software$503.9M+6% YoY

Growth in MEDIFOX DAN, Home and Hospice, and HME verticals, partially offset by weaker Senior Living and Long-Term Care performance.

Largest Expense Items

Cost of sales$1,575.8M+2% YoY

Manufacturing and logistics efficiencies and component cost improvements contributed to gross margin expansion to 61.8% from 58.8%.

Selling, general, and administrative$823.2M+13% YoY

Employee-related costs, VirtuOx acquisition expenses, marketing and technology investments, plus $5.9M acquisition and portfolio review charges.

Research and development$272.6M+11% YoY

Increased employee-related costs supporting new product development and commercialization.

Watch Items from the Filing

Multiple ongoing patent infringement litigations with Cleveland Medical, NYU, and Fractus; PTAB decisions mostly favorable but Federal Circuit appeals pending; potential material exposure if outcomes reverse.
Senior Notes of $250M due July 10, 2026; company has $1.66B cash and full access to $1.5B revolving credit facility; refinancing risk is low.
Effective tax rate of 21.1% increased from 16.3% YoY, driven by Pillar Two global minimum tax implementation; Singapore tax holidays expire through June 2030.
Constant currency revenue growth of 8% YoY (vs. 10% reported), with international FX benefiting Sleep and Breathing Health +$71.2M; EUR and AUD strength supported results.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q3 2026

$1.4B

Net Income

Q3 2026

$398.7M

Free Cash Flow

Q3 2026

$520.5M

Operating Margin

Q3 2026

34.9%

D/E Ratio

Q3 2026

0.10

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+9.8% YoY

$5.15BFY 2025

FY22 $3.58BFY23 $4.22BFY24 $4.69BFY25 $5.15B

Net Income

+37.2% YoY

$1.40BFY 2025

FY22 $779.4MFY23 $897.6MFY24 $1.02BFY25 $1.40B

Operating Income

+27.7% YoY

$1.69BFY 2025

FY22 $1.00BFY23 $1.13BFY24 $1.32BFY25 $1.69B

EPS (Diluted)

+37.4% YoY

$9.51FY 2025

FY22 $5.30FY23 $6.09FY24 $6.92FY25 $9.51

Total Assets

+18.9% YoY

$8.17BFY 2025

FY22 $5.10BFY23 $6.75BFY24 $6.87BFY25 $8.17B

Total Debt

-5.5% YoY

$668.3MFY 2025

FY22 $775.2MFY23 $1.44BFY24 $707.2MFY25 $668.3M

Op. Cash Flow

+25.0% YoY

$1.75BFY 2025

FY22 $351.1MFY23 $693.3MFY24 $1.40BFY25 $1.75B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$5.15B +9.8%	$4.69B +10.9%	$4.22B +18.0%	$3.58B +11.9%	$3.20B +8.1%	$2.96B
Net Income	$1.40B +37.2%	$1.02B +13.7%	$897.6M +15.2%	$779.4M +64.3%	$474.5M -23.7%	$621.7M
Operating Income	$1.69B +27.7%	$1.32B +16.6%	$1.13B +13.2%	$1.00B +10.7%	$903.7M +11.6%	$809.7M
EPS (Diluted)	$9.51 +37.4%	$6.92 +13.6%	$6.09 +14.9%	$5.30 +63.6%	$3.24 -24.1%	$4.27
Total Assets	$8.17B +18.9%	$6.87B +1.8%	$6.75B +32.5%	$5.10B +7.8%	$4.73B +3.1%	$4.59B
Total Debt	$668.3M -5.5%	$707.2M -50.9%	$1.44B +85.9%	$775.2M +18.3%	$655.4M -44.3%	$1.18B
Operating Cash Flow	$1.75B +25.0%	$1.40B +102.1%	$693.3M +97.4%	$351.1M -52.3%	$736.7M -8.2%	$802.3M

AI Insight: RMD Financial Trends

ResMed delivers steady top- and bottom-line compounding, with revenue up 17% and operating income up 31% from Q2 2024 to Q1 2026 while debt barely moves.

• Operating income expanded from $381M in Q2 2024 to $500M in Q1 2026, lifting implied op margin from ~31% to ~35%.

• Revenue grew consistently from $1,223M in Q2 2024 to $1,431M in Q1 2026, an eight-quarter unbroken uptrend.

• Total debt declined modestly from $707M in Q2 2024 to $664M in Q1 2026 while equity rose from $4,864M to $6,492M, cutting leverage materially.

• Net income dipped to $349M in Q3 2025 from $380M in Q2 2025 before recovering to $399M in Q1 2026 — a brief mid-cycle soft patch.

⚠ Operating cash flow remains lumpy: $309M in Q4 2024 and $340M in Q4 2025 versus $554M in Q1 2026 — seasonal working-capital swings bear monitoring.

⚠ Q3 2025 revenue dipped sequentially to $1,336M from $1,348M — first sequential decline in the series; watch whether Q4 2025 rebound is sustained.

AI Insight: RMD Ratio Trends

Operating margin hit a series high of 34.9% in Q1 2026, while leverage dropped to 0.10 D/E — balance sheet and profitability both strengthening.

• Operating margin expanded steadily from 31.2% in Q2 2024 to 34.9% in Q1 2026, a 370bp improvement over seven quarters.

• D/E ratio declined from 0.15 in Q2 2024 to 0.10 in Q1 2026, signaling consistent deleveraging.

• ROE and ROA dipped in Q3 2025 to 22.8% and 16.8% respectively before partially recovering to 24.6% and 18.2% in Q1 2026.

⚠ ROIC of 27.9% in Q1 2026 remains below the Q4 2024 peak of 28.2% — watch for sustained recovery above that level.

⚠ NPM dipped sharply to 26.1% in Q3 2025 from 28.3% in Q1 2025; one-off or structural pressure warrants monitoring.

Get alerted when RMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RESMED INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RMD

BlackRock, Inc.
$2.7B12,094,023 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.1B9,466,416 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.8B7,863,922 sh
STATE STREET CORP
$1.5B6,643,168 sh
Bank of New York Mellon Corp
$1.1B4,925,386 sh
GEODE CAPITAL MANAGEMENT, LLC
$973.8M4,352,873 sh
MORGAN STANLEY
$603.1M2,686,821 sh
Invesco Ltd.
$439.2M1,956,614 sh
NORTHERN TRUST CORP
$387.4M1,725,693 sh
FIRST TRUST ADVISORS LP
$345.2M1,537,825 sh

Fund	Value	Shares
BlackRock, Inc.	$2.7B	12,094,023
VANGUARD CAPITAL MANAGEMENT LLC	$2.1B	9,466,416
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.8B	7,863,922
STATE STREET CORP	$1.5B	6,643,168
Bank of New York Mellon Corp	$1.1B	4,925,386
GEODE CAPITAL MANAGEMENT, LLC	$973.8M	4,352,873
MORGAN STANLEY	$603.1M	2,686,821
Invesco Ltd.	$439.2M	1,956,614
NORTHERN TRUST CORP	$387.4M	1,725,693
FIRST TRUST ADVISORS LP	$345.2M	1,537,825

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RMD on your watchlist

Track score changes the day RESMED INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RMD a good stock to buy?

13F Pro's AI-powered analysis of RESMED INC (RMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RMD are available on the RMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RESMED INC's investment landscape.